Puma Biotechnology, Inc.

Total Valuation

Puma Biotechnology, Inc. carries a market capitalization of 355.28M, placing it among publicly traded companies globally. Its enterprise value stands at 235.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Puma Biotechnology, Inc. currently has 50.88M shares outstanding.

Valuation Ratios

Puma Biotechnology, Inc. trades at a trailing price-to-earnings ratio of 13.18. The price-to-sales ratio is 1.41, and the price-to-book ratio stands at -0.25.

Enterprise Valuation

On an enterprise value basis, Puma Biotechnology, Inc. trades at an EV/EBITDA multiple of 5.87 and an EV/FCF ratio of 4.07. The EV/Sales ratio of 1.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.00 provides insight into valuation relative to core operating earnings.

Financial Position

Puma Biotechnology, Inc. maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.42, indicating elevated leverage, while an interest coverage ratio of 7.77 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Puma Biotechnology, Inc. has paid 4.70M in income taxes, reflecting an effective tax rate of 16.17.

Stock Price Statistics

Puma Biotechnology, Inc.'s stock has gained approximately 110.24096% over the past 52 weeks. The 50-day moving average sits at 7.13, while the 200-day moving average is 6.01.

Income Statement

Over the trailing twelve months, Puma Biotechnology, Inc. generated 227.18M in revenue and converted that into 24.38M in net income, yielding earnings per share of 0.48. EBITDA reached 40.21M, while operating income came in at 29.49M.

Balance Sheet

Puma Biotechnology, Inc. holds 101.55M in cash and equivalents against 15.95M in total debt, resulting in a net debt position of -24.91M. Total book value stands at -1.29B, with working capital of 82.52M providing operational flexibility.

Cash Flow

Puma Biotechnology, Inc. produced 53.61M in operating cash flow over the past twelve months. After subtracting -10,000.00 in capital expenditures, free cash flow totaled 53.60M - equivalent to 1.07 per share.

Margins

Puma Biotechnology, Inc. operates with a gross margin of 74.46, reflecting its pricing power and cost economics. The operating margin of 12.98 and net profit margin of 10.73 provide insight into operational efficiency.

Dividends & Yields

Scores

Puma Biotechnology, Inc. posts an Altman Z-Score of -5.97, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.